 |
The Unraveling of Incretin Biology: New Dimensions in the Management of Type 2 Diabetes CME Edward S. Horton, MD, Activity Chairperson; Jack L. Leahy, MD; Michael A. Nauck, MD, PhD Author Information and Disclosures Release Date: August 27, 2008; Valid for credit through August 27, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.
This CME activity is based on a satellite symposium held in conjunction with the American Diabetes Association's 68th Scientific Sessions, which took place on June 8, 2008, at the Hilton San Francisco, in San Francisco, California. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 by SciMed. All rights reserved. These materials are for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of SciMed is prohibited. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review the implications of islet cell dysfunction for the pathogenesis and progression of type 2 diabetes.
- Describe the physiologic effects of incretin hormones on islet cell dysfunction and glucose homeostasis.
- Utilize best evidence when
considering incretin mimetics and DPP-4 inhibitors for the management of patients with type 2 diabetes.
Authors and Disclosures Edward S. Horton, MD
Disclosure: Grants/Research Support: Amylin Pharmaceuticals, Eli Lilly and Company; Consultant: Abbott Laboratories, GlaxoSmithKline, Innodia, Merck & Co., Inc., Novartis,
sanofi-aventis, Takeda Pharmaceuticals Inc. Jack L. Leahy, MD
Disclosure: Consultant: Merck & Co., Inc., Novo Nordisk, sanofi-aventis; Speakers Bureau: Merck & Co., Inc., sanofi-aventis Michael A. Nauck, MD, PhD
Disclosure: Grants/Research Support: Amylin Pharmaceuticals, Bayer Vital, Berlin-Chemie/Menarini, Eli Lilly and
Company, Novartis, Novo Nordisk, Probiodrug, Restoragen Inc., sanofi-aventis; Consultant: AstraZeneca, Bayer Vital, Berlin-Chemie/Menarini, Biovitrum, ConjuChem, Inc., Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Inc., MSD, Novartis, Novo Nordisk, Pfizer Inc, Probiodrug, Restoragen Inc., sanofi-aventis, Takeda Pharmaceuticals Inc.; Advisory Boards: Amylin Pharmaceuticals, ConjuChem, Inc., Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche, Novartis, Novo
Nordisk, Probiodrug, Restoragen Inc., sanofi-aventis |
 |
SciMed is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SciMed designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
